Investor Relations

23andMe is a leading consumer genetics and research company. Founded in 2006, our mission is to help people access, understand, and benefit from the human genome. We want to disrupt the healthcare experience by building a personalized health and wellness experience that caters uniquely to the individual by harnessing the power of their DNA. 23andMe pioneered direct access to genetic information as the only company with multiple FDA clearances for genetic health reports.

We have built the world’s largest crowdsourced platform for genetic research, with 80 percent of our customers electing to participate. This platform allows us to accelerate research at an unprecedented scale, while providing information back to participants. Our Therapeutics team leverages this research platform to identify and develop drug targets rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases.